ArticleHeadache2020

Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan.

David Kudrow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.